Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: synthetic macrocycles - Ensemble Therapeutics

Next Previous
Drug Profile

Research programme: synthetic macrocycles - Ensemble Therapeutics

Alternative Names: E-36041; IDO checkpoint inhibitors; ubiquitin proteasome inhibitors

Latest Information Update: 24 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ensemble Discovery
  • Developer Ensemble Therapeutics; Novartis
  • Class Antineoplastics; Macrocyclic compounds; Small molecules
  • Mechanism of Action Checkpoint kinase inhibitors; Cyclophilin D inhibitors; Cyclophilin inhibitors; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Inhibitor of apoptosis protein inhibitors; Interleukin 17 receptor antagonists; PCSK9 protein inhibitors; Tryptophan oxygenase inhibitors; Ubiquitin thiolesterase modulators; USP28 protein inhibitors; Usp30 protein inhibitors; USP9X protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Cancer; Cardiovascular disorders; Diabetes mellitus; Hepatitis B; Inflammation; Pain; Parkinson's disease; Reperfusion injury; Rheumatoid arthritis

Most Recent Events

  • 24 Feb 2023 Discontinued - Preclinical for Cancer in USA (PO)
  • 24 Feb 2023 Discontinued - Preclinical for Inflammation in USA (PO) (Novartis pipeline, February 2023)
  • 24 Feb 2023 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO) (Novartis pipeline, February 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top